Advertisement

Topics

Catalent pushes into gene therapy with $1.2 billion buyout of Paragon Bioservices

10:42 EDT 15 Apr 2019 | Reuters

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.

Original Article: Catalent pushes into gene therapy with $1.2 billion buyout of Paragon Bioservices

NEXT ARTICLE

More From BioPortfolio on "Catalent pushes into gene therapy with $1.2 billion buyout of Paragon Bioservices"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...